RapamycinFungusV1, Main, Exploration, bibRecord, 000D76

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

Identifieur interne : 000D76 ( Main/Exploration ); précédent : 000D75; suivant : 000D77

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

Auteurs : Zhuo Wang [République populaire de Chine] ; Wei Jin [République populaire de Chine] ; Hongchuan Jin [République populaire de Chine] ; Xian Wang [République populaire de Chine]

Source :

BioMed research international [ 2314-6141 ] ; 2014.

RBID : pubmed:24804240

Descripteurs français

KwdFr :
- Animaux (MeSH), Carcinome hépatocellulaire (anatomopathologie), Carcinome hépatocellulaire (génétique), Carcinome hépatocellulaire (traitement médicamenteux), Femelle (MeSH), Humains (MeSH), Hépatite (génétique), Hépatite (traitement médicamenteux), Hépatite (virologie), Inhibiteurs de protéines kinases (administration et posologie), Mâle (MeSH), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérine-thréonine kinases TOR (génétique), Tumeurs du foie (anatomopathologie), Tumeurs du foie (génétique), Tumeurs du foie (traitement médicamenteux).
MESH :
- administration et posologie : Inhibiteurs de protéines kinases.
- anatomopathologie : Carcinome hépatocellulaire, Tumeurs du foie.
- antagonistes et inhibiteurs : Sérine-thréonine kinases TOR.
- génétique : Carcinome hépatocellulaire, Hépatite, Sérine-thréonine kinases TOR, Tumeurs du foie.
- traitement médicamenteux : Carcinome hépatocellulaire, Hépatite, Tumeurs du foie.
- virologie : Hépatite.
- Animaux, Femelle, Humains, Mâle.

English descriptors

KwdEn :
- Animals (MeSH), Carcinoma, Hepatocellular (drug therapy), Carcinoma, Hepatocellular (genetics), Carcinoma, Hepatocellular (pathology), Female (MeSH), Hepatitis (drug therapy), Hepatitis (genetics), Hepatitis (virology), Humans (MeSH), Liver Neoplasms (drug therapy), Liver Neoplasms (genetics), Liver Neoplasms (pathology), Male (MeSH), Protein Kinase Inhibitors (administration & dosage), TOR Serine-Threonine Kinases (antagonists & inhibitors), TOR Serine-Threonine Kinases (genetics).
MESH :
- chemical , administration & dosage : Protein Kinase Inhibitors.
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- drug therapy : Carcinoma, Hepatocellular, Hepatitis, Liver Neoplasms.
- genetics : Carcinoma, Hepatocellular, Hepatitis, Liver Neoplasms, TOR Serine-Threonine Kinases.
- pathology : Carcinoma, Hepatocellular, Liver Neoplasms.
- virology : Hepatitis.
- Animals, Female, Humans, Male.

Abstract

As the fifth most common cancer in men and the eighth most common cancer in women, hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide, with standard chemotherapy and radiation being minimally effective in prolonging survival. Virus hepatitis, particularly HBV and HCV infection is the most prominent risk factor for HCC development. Mammalian target of rapamycin (mTOR) pathway is activated in viral hepatitis and HCC. mTOR inhibitors have been tested successfully in clinical trials for their antineoplastic potency and well tolerability. Treatment with mTOR inhibitor alone or in combination with cytotoxic drugs or targeted therapy drug scan significantly reduces HCC growth and improves clinical outcome, indicating that mTOR inhibition is a promising strategy for the clinical management of HCC.

DOI: 10.1155/2014/735672
PubMed: 24804240
PubMed Central: PMC3996896

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000E53
to stream Main, to step Curation: 000E53

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.</title>
<author><name sortKey="Wang, Zhuo" sort="Wang, Zhuo" uniqKey="Wang Z" first="Zhuo" last="Wang">Zhuo Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Jin, Wei" sort="Jin, Wei" uniqKey="Jin W" first="Wei" last="Jin">Wei Jin</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Jin, Hongchuan" sort="Jin, Hongchuan" uniqKey="Jin H" first="Hongchuan" last="Jin">Hongchuan Jin</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Xian" sort="Wang, Xian" uniqKey="Wang X" first="Xian" last="Wang">Xian Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24804240</idno>
<idno type="pmid">24804240</idno>
<idno type="doi">10.1155/2014/735672</idno>
<idno type="pmc">PMC3996896</idno>
<idno type="wicri:Area/Main/Corpus">000E53</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E53</idno>
<idno type="wicri:Area/Main/Curation">000E53</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000E53</idno>
<idno type="wicri:Area/Main/Exploration">000E53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.</title>
<author><name sortKey="Wang, Zhuo" sort="Wang, Zhuo" uniqKey="Wang Z" first="Zhuo" last="Wang">Zhuo Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Jin, Wei" sort="Jin, Wei" uniqKey="Jin W" first="Wei" last="Jin">Wei Jin</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Jin, Hongchuan" sort="Jin, Hongchuan" uniqKey="Jin H" first="Hongchuan" last="Jin">Hongchuan Jin</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
<author><name sortKey="Wang, Xian" sort="Wang, Xian" uniqKey="Wang X" first="Xian" last="Wang">Xian Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou</wicri:regionArea>
<placeName><settlement type="city">Hangzhou</settlement>
<region type="province">Zhejiang</region>
</placeName>
<orgName type="university">Université de Zhejiang</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">BioMed research international</title>
<idno type="eISSN">2314-6141</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Carcinoma, Hepatocellular (drug therapy)</term>
<term>Carcinoma, Hepatocellular (genetics)</term>
<term>Carcinoma, Hepatocellular (pathology)</term>
<term>Female (MeSH)</term>
<term>Hepatitis (drug therapy)</term>
<term>Hepatitis (genetics)</term>
<term>Hepatitis (virology)</term>
<term>Humans (MeSH)</term>
<term>Liver Neoplasms (drug therapy)</term>
<term>Liver Neoplasms (genetics)</term>
<term>Liver Neoplasms (pathology)</term>
<term>Male (MeSH)</term>
<term>Protein Kinase Inhibitors (administration & dosage)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
<term>TOR Serine-Threonine Kinases (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term>
<term>Carcinome hépatocellulaire (anatomopathologie)</term>
<term>Carcinome hépatocellulaire (génétique)</term>
<term>Carcinome hépatocellulaire (traitement médicamenteux)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hépatite (génétique)</term>
<term>Hépatite (traitement médicamenteux)</term>
<term>Hépatite (virologie)</term>
<term>Inhibiteurs de protéines kinases (administration et posologie)</term>
<term>Mâle (MeSH)</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Sérine-thréonine kinases TOR (génétique)</term>
<term>Tumeurs du foie (anatomopathologie)</term>
<term>Tumeurs du foie (génétique)</term>
<term>Tumeurs du foie (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Protein Kinase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome hépatocellulaire</term>
<term>Tumeurs du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Hepatocellular</term>
<term>Hepatitis</term>
<term>Liver Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Hepatocellular</term>
<term>Hepatitis</term>
<term>Liver Neoplasms</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Carcinome hépatocellulaire</term>
<term>Hépatite</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Tumeurs du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Hepatocellular</term>
<term>Liver Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome hépatocellulaire</term>
<term>Hépatite</term>
<term>Tumeurs du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As the fifth most common cancer in men and the eighth most common cancer in women, hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide, with standard chemotherapy and radiation being minimally effective in prolonging survival. Virus hepatitis, particularly HBV and HCV infection is the most prominent risk factor for HCC development. Mammalian target of rapamycin (mTOR) pathway is activated in viral hepatitis and HCC. mTOR inhibitors have been tested successfully in clinical trials for their antineoplastic potency and well tolerability. Treatment with mTOR inhibitor alone or in combination with cytotoxic drugs or targeted therapy drug scan significantly reduces HCC growth and improves clinical outcome, indicating that mTOR inhibition is a promising strategy for the clinical management of HCC. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24804240</PMID>
<DateCompleted><Year>2015</Year>
<Month>01</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2314-6141</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2014</Volume>
<PubDate><Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>BioMed research international</Title>
<ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
</Journal>
<ArticleTitle>mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.</ArticleTitle>
<Pagination><MedlinePgn>735672</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/735672</ELocationID>
<Abstract><AbstractText>As the fifth most common cancer in men and the eighth most common cancer in women, hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide, with standard chemotherapy and radiation being minimally effective in prolonging survival. Virus hepatitis, particularly HBV and HCV infection is the most prominent risk factor for HCC development. Mammalian target of rapamycin (mTOR) pathway is activated in viral hepatitis and HCC. mTOR inhibitors have been tested successfully in clinical trials for their antineoplastic potency and well tolerability. Treatment with mTOR inhibitor alone or in combination with cytotoxic drugs or targeted therapy drug scan significantly reduces HCC growth and improves clinical outcome, indicating that mTOR inhibition is a promising strategy for the clinical management of HCC. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Zhuo</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Hongchuan</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Xian</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>04</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Biomed Res Int</MedlineTA>
<NlmUniqueID>101600173</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006505" MajorTopicYN="N">Hepatitis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>11</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>03</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>1</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24804240</ArticleId>
<ArticleId IdType="doi">10.1155/2014/735672</ArticleId>
<ArticleId IdType="pmc">PMC3996896</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Mol Cell. 2010 Jun 11;38(5):768-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20542007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Amino Acids. 2012 Dec;43(6):2561-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22566039</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aliment Pharmacol Ther. 2013 Jan;37(1):62-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23134470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer. 2005 Jan 15;103(2):307-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15593087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dig Dis Sci. 2008 Mar;53(3):844-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17763954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2002 Sep;76(18):9207-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12186904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Oncol. 2010 Jun;27(2):255-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19301157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Feb 9;366(6):520-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22149876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Aug;86(16):8705-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22674982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1998 Jun 5;273(23):14484-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9603962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Metab. 2008 Sep;8(3):224-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18762023</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2007 Apr 20;282(16):11836-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17255101</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Genet. 2004 Jun;36(6):585-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15146184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2004 Aug 15;18(16):1926-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15314020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2013 Jul;24(7):1900-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23519998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15508102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18929564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Oncol. 2009 Dec;36 Suppl 3:S26-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19963097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2007 Dec 15;21(24):3232-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18055695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Cell Biol. 2008 Aug;10(8):935-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18604198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2004 Jul 1;18(13):1533-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15231735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Biol Ther. 2008 Mar;7(3):392-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18075305</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2006 Apr 21;22(2):159-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16603397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2003 Dec;163(6):2441-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14633616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 2012 May;55(5):1473-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22271091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2008 Jul;7(7):1782-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18644990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Oncol. 2012 Oct;41(4):1381-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22895785</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 2010 Dec;30(12):4951-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21187475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2013 Dec;59(6):1271-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23928403</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2012 Aug 10;47(3):349-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22749528</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2004 Jul;6(1):91-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15261145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 2005 Jul 12;44(27):9417-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15996096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2005 Jun;206(2):214-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15880754</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2011 Mar;140(3):1071-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21147110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Lett. 2009 Jan 18;273(2):201-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18824293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Biochem Sci. 2012 Aug;37(8):309-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22626471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2002 Sep 26;21(43):6587-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12242656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2003 Dec;112(12):1809-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14638851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2011 May 27;145(5):732-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21620138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Invest New Drugs. 2011 Dec;29(6):1177-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20524035</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2008 Jul;49(1):78-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18486258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Cell Biol. 2004 Nov;6(11):1122-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15467718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Cell Biol. 2005 Apr;17(2):158-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15780592</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(7):e41931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22848663</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 2011 Oct;54(4):1199-207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21735472</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 1998 Aug 13;17(6):769-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9715279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2010 Apr;52(4):594-604</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20185200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1991 Sep 15;51(18):4971-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1654208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2008 Jan;134(1):268-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18166358</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2005 Sep;5(9):558-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16122679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2010 Jul 30;39(2):171-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20670887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Sep;81(18):10072-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17609269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Cell Biol. 2007 Mar;9(3):316-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17277771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ernst Schering Found Symp Proc. 2007;(4):99-124</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18811055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2002 Feb 1;62(3):642-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11830512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2004 Dec;3(12):1605-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15634654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2007 Aug;12(2):108-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17692803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2012 Aug 17;150(4):685-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22901803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2012 Jun 20;4(139):139ra84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22539746</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2009 Feb 3;15(2):148-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19185849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Feb 10;364(6):514-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21306238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2010 Nov 4;363(19):1801-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21047224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2008 Aug 9;372(9637):449-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18653228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2002 Sep;10(3):457-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12408816</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1997 Oct 17;272(42):26457-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9334222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2010 Mar 16;17(3):249-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20227039</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2007 May;46(5):840-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17321636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World J Hepatol. 2013 Jan 27;5(1):43-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23383366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Ther. 2002 Feb-Mar;93(2-3):243-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12191616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Pharmacol. 2012 May 1;83(9):1146-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22285225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2010 Jul 2;285(27):20870-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20439463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Cancer. 2008;8:282</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18831768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2013 Feb;123(2):630-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23321675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2010 Oct 22;40(2):310-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20965424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2008 Jul;49(1):52-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18490075</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2002 Jul 26;110(2):163-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12150925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hepatology. 2009 Jun;49(6):1962-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19475690</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2004 Dec 15;10(24):8421-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15623621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2006 Aug 7;580(18):4392-400</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16844119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncol Rep. 2011 Nov;26(5):1273-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21725613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2007 Jul 13;282(28):20534-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17502379</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biochem. 2013 Jan;372(1-2):161-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23001846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Clin Oncol. 2008 Feb;13(1):66-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18307022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2007 Oct;7(10):763-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17882277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Biol. 2004 Jul 27;14(14):1296-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15268862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2008 Nov;8(11):851-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18846101</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2008 Jun 13;320(5882):1496-501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18497260</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2007 Mar 23;25(6):903-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17386266</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Cancer. 2012;12:166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22559167</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<region><li>Zhejiang</li>
</region>
<settlement><li>Hangzhou</li>
</settlement>
<orgName><li>Université de Zhejiang</li>
</orgName>
</list>
<tree><country name="République populaire de Chine"><region name="Zhejiang"><name sortKey="Wang, Zhuo" sort="Wang, Zhuo" uniqKey="Wang Z" first="Zhuo" last="Wang">Zhuo Wang</name>
</region>
<name sortKey="Jin, Hongchuan" sort="Jin, Hongchuan" uniqKey="Jin H" first="Hongchuan" last="Jin">Hongchuan Jin</name>
<name sortKey="Jin, Wei" sort="Jin, Wei" uniqKey="Jin W" first="Wei" last="Jin">Wei Jin</name>
<name sortKey="Wang, Xian" sort="Wang, Xian" uniqKey="Wang X" first="Xian" last="Wang">Xian Wang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D76 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D76 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:24804240
   |texte=   mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24804240" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki